ES3060133T3 - Composition and method of treating cancer associated with egfr mutation - Google Patents
Composition and method of treating cancer associated with egfr mutationInfo
- Publication number
- ES3060133T3 ES3060133T3 ES19810149T ES19810149T ES3060133T3 ES 3060133 T3 ES3060133 T3 ES 3060133T3 ES 19810149 T ES19810149 T ES 19810149T ES 19810149 T ES19810149 T ES 19810149T ES 3060133 T3 ES3060133 T3 ES 3060133T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- treating cancer
- cancer associated
- egfr mutation
- plinabulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679619P | 2018-06-01 | 2018-06-01 | |
| PCT/US2019/034726 WO2019232257A1 (en) | 2018-06-01 | 2019-05-30 | Composition and method of treating cancer associated with egfr mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3060133T3 true ES3060133T3 (en) | 2026-03-25 |
Family
ID=68696755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19810149T Active ES3060133T3 (en) | 2018-06-01 | 2019-05-30 | Composition and method of treating cancer associated with egfr mutation |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210161888A1 (https=) |
| EP (1) | EP3801524B1 (https=) |
| JP (1) | JP7500438B2 (https=) |
| KR (1) | KR102790127B1 (https=) |
| CN (1) | CN112543636B (https=) |
| AU (1) | AU2019278886B2 (https=) |
| CA (1) | CA3101612A1 (https=) |
| DK (1) | DK3801524T3 (https=) |
| ES (1) | ES3060133T3 (https=) |
| MX (1) | MX420412B (https=) |
| WO (1) | WO2019232257A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| AU2022357570A1 (en) * | 2021-10-03 | 2024-04-11 | Systimmune, Inc. | Methods of treating cancer and the pharmaceutical compositions thereof |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| EP4719416A1 (en) * | 2023-06-02 | 2026-04-08 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0313363A (pt) * | 2002-08-02 | 2005-08-09 | Nereus Pharmaceuticals Inc | Deidrofenilahistinas e seus análogos, e sua sìntese |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| US20110160159A1 (en) * | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| AU2016219204B2 (en) * | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
| MX383691B (es) * | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| AU2018236168B2 (en) * | 2017-03-13 | 2024-02-29 | Beyondspring Pharmaceuticals, Inc. | Compositions of plinabulin and use thereof |
-
2019
- 2019-05-30 ES ES19810149T patent/ES3060133T3/es active Active
- 2019-05-30 US US17/059,694 patent/US20210161888A1/en not_active Abandoned
- 2019-05-30 JP JP2020567029A patent/JP7500438B2/ja active Active
- 2019-05-30 KR KR1020207036949A patent/KR102790127B1/ko active Active
- 2019-05-30 CA CA3101612A patent/CA3101612A1/en active Pending
- 2019-05-30 MX MX2020012799A patent/MX420412B/es unknown
- 2019-05-30 AU AU2019278886A patent/AU2019278886B2/en active Active
- 2019-05-30 EP EP19810149.5A patent/EP3801524B1/en active Active
- 2019-05-30 CN CN201980050963.3A patent/CN112543636B/zh active Active
- 2019-05-30 WO PCT/US2019/034726 patent/WO2019232257A1/en not_active Ceased
- 2019-05-30 DK DK19810149.5T patent/DK3801524T3/da active
-
2025
- 2025-05-23 US US19/217,307 patent/US20250375440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3801524T3 (da) | 2026-02-02 |
| US20250375440A1 (en) | 2025-12-11 |
| US20210161888A1 (en) | 2021-06-03 |
| KR102790127B1 (ko) | 2025-04-03 |
| JP2021525768A (ja) | 2021-09-27 |
| CN112543636B (zh) | 2024-03-01 |
| EP3801524A1 (en) | 2021-04-14 |
| MX420412B (es) | 2025-02-10 |
| JP7500438B2 (ja) | 2024-06-17 |
| CA3101612A1 (en) | 2019-12-05 |
| CN112543636A (zh) | 2021-03-23 |
| EP3801524B1 (en) | 2025-11-05 |
| KR20210015875A (ko) | 2021-02-10 |
| AU2019278886B2 (en) | 2025-03-20 |
| AU2019278886A1 (en) | 2020-12-24 |
| WO2019232257A1 (en) | 2019-12-05 |
| MX2020012799A (es) | 2021-03-25 |
| EP3801524A4 (en) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3060133T3 (en) | Composition and method of treating cancer associated with egfr mutation | |
| CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| MX374501B (es) | Formulaciones de anticuerpos de her2 subcutáneas. | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| ECSP19042682A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| MX2017013178A (es) | Terapia de combinacion para cancer. | |
| CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
| MX2020008184A (es) | Receptores de antigeno quimericos dirigidos a cd70. | |
| ES3060430T3 (en) | Anti-btn3a antibodies and their use in treating cancer or infectious disorders | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
| MX2016003103A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores. | |
| ES2422605T3 (es) | Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares | |
| MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
| BR112018013725A2 (pt) | combinações anti-her2 para o tratamento de tumores | |
| MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
| MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
| BR112022012885A2 (pt) | Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 |